195 related articles for article (PubMed ID: 30931902)
1. [Improving efficacy of cancer immunotherapy through targeting of macrophages].
Peranzoni E; Donnadieu E
Med Sci (Paris); 2019 Mar; 35(3):207-209. PubMed ID: 30931902
[No Abstract] [Full Text] [Related]
2. Are peptide vaccines viable in combination with other cancer immunotherapies?
Ohtake J; Sasada T
Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424
[No Abstract] [Full Text] [Related]
3. [Anti-cancer vaccines: What future in anti-cancer immunotherapy strategies?].
Tartour E
Biol Aujourdhui; 2018; 212(3-4):69-76. PubMed ID: 30973134
[TBL] [Abstract][Full Text] [Related]
4. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of cancer: targeting cancer during active disease or during dormancy?
Shah SA; Zarei M; Manjili SH; Guruli G; Wang XY; Manjili MH
Immunotherapy; 2017 Sep; 9(11):943-949. PubMed ID: 29338608
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy.
Andersson P; Ostheimer C
Front Immunol; 2019; 10():2083. PubMed ID: 31555290
[No Abstract] [Full Text] [Related]
8. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic immunotherapy: an emerging new modality for the treatment of cancer.
Coffin RS
Ann Oncol; 2016 Sep; 27(9):1805-8. PubMed ID: 27166292
[No Abstract] [Full Text] [Related]
10. Efficacy of immunotherapy, gut microbiota and impact of antibiotic use: are there confounding factors?
Milano G
Cancer Chemother Pharmacol; 2019 Jul; 84(1):223-224. PubMed ID: 30980131
[No Abstract] [Full Text] [Related]
11. Antibody Therapies in Cancer.
Wang S; Jia M
Adv Exp Med Biol; 2016; 909():1-67. PubMed ID: 27240456
[TBL] [Abstract][Full Text] [Related]
12. [TGF-β-targeted immunotherapy aiming for new and efficient treatments of cancer].
Foughali R; Marie JC
Med Sci (Paris); 2020 Jan; 36(1):77-79. PubMed ID: 32014103
[No Abstract] [Full Text] [Related]
13. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.
Nishida S; Sugiyama H
Methods Mol Biol; 2016; 1467():221-32. PubMed ID: 27417973
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of efficacy in cancer immunotherapy: 14th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 10-12, 2016.
Theelen J; Braun J; Hörzer H; Kloke BP; Ott M; Pizzitola I; Schirmer U; Miller M
Cancer Immunol Immunother; 2017 May; 66(5):673-681. PubMed ID: 28251274
[No Abstract] [Full Text] [Related]
16. Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess.
Ciccolini J; Barbolosi D; André N; Benzekry S; Barlesi F
Ann Oncol; 2019 Nov; 30(11):1690-1691. PubMed ID: 31504149
[No Abstract] [Full Text] [Related]
17. Neoantigens in the immuno-oncology space.
Arlen PM
Future Oncol; 2017 Oct; 13(25):2209-2211. PubMed ID: 28976211
[No Abstract] [Full Text] [Related]
18. Immunotherapy in colorectal cancer.
Le DT
Clin Adv Hematol Oncol; 2018 Jan; 16(1):22-24. PubMed ID: 29741500
[No Abstract] [Full Text] [Related]
19. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.
Ries CH; Hoves S; Cannarile MA; Rüttinger D
Curr Opin Pharmacol; 2015 Aug; 23():45-51. PubMed ID: 26051995
[TBL] [Abstract][Full Text] [Related]
20. Combined GM-CSF treatment and M-CSF inhibition of tumor-associated macrophages induces dendritic cell-like signaling in vitro.
Kitoh Y; Saio M; Gotoh N; Umemura N; Nonaka K; Bai J; Vizkeleti L; Torocsik D; Balazs M; Adany R; Takami T
Int J Oncol; 2011 May; 38(5):1409-19. PubMed ID: 21373754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
